NRX Pharmaceuticals Inc

Description

NRX Pharmaceuticals, Inc. is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure (the NRx COVID-19 Drug). It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior the NRx Antidepressant Drug Regimen. The company is headquartered in Wilmington, DE.